The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be
safe and well tolerated. Further, pH control will be evaluated in the distal esophageal
mucosa and just below the squamocolumnar junction.